RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $275 Price Target
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a $275 price target.
May 31, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Luca Issi reiterates an Outperform rating on Alnylam Pharmaceuticals and maintains a $275 price target.
The Outperform rating and maintained price target by RBC Capital indicate a positive outlook for Alnylam Pharmaceuticals. This news is directly related to ALNY and is important for investors as it suggests potential growth in the stock's value. The confidence in this analysis is high due to the reputation of RBC Capital and their analyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100